camrelizumab + pemetrexed + carboplatin

Camrelizumab + pemetrexed + carboplatin is a combination regimen used as first-line therapy for advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR or ALK genomic alterations. Camrelizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Pemetrexed is an antifolate chemotherapy agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while carboplatin is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis in rapidly dividing cells. This combination has demonstrated significant improvements in progression-free survival and overall survival compared to chemotherapy alone, and has received regulatory approval as standard-of-care first-line therapy for this NSCLC population[1][2][3][4].

Brand names

AiRuiKa (camrelizumab)Alimta (pemetrexed)